Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Advanced Accelerator Applications
Deal Size : $172.0 million
Deal Type : Agreement
Details : Advanced Accelerator Applications (AAA) and Endocyte, Inc., both Novartis companies, successfully completed full-scale development of Pluvicto and also received Breakthrough Therapy designation from the U.S. FDA last year.
Brand Name : Pluvicto
Molecule Type : Large molecule
Upfront Cash : $12.0 million
March 29, 2022
Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Advanced Accelerator Applications
Deal Size : $172.0 million
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Reset All
